The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Joshua J Meeks
Honoraria - CG Oncology; Foundation Medicine; Janssen; Merck; Nucleix
Consulting or Advisory Role - AstraZeneca; Ferring; Merck
Research Funding - Epizyme; Merck Sharp & Dohme
Travel, Accommodations, Expenses - AstraZeneca; Merck Sharp & Dohme
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Hiroyuki Nishiyama
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Janssen; Lilly
Speakers' Bureau - Chugai Pharma; MSD
Research Funding - Astellas Pharma (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Hikmat A Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Janssen Biotech
 
Erik T. Goluboff
Employment - AstraZeneca
 
Stephan Hois
Employment - AstraZeneca; Novartis
Stock and Other Ownership Interests - Novartis
 
Sarah E. Donegan
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Vanessa Williams
Employment - AstraZeneca
 
Feng Xiao
Employment - AstraZeneca
 
James WF Catto
Honoraria - Abbott Laboratories
Consulting or Advisory Role - AstraZeneca/MedImmune; Ferring; Janssen
Speakers' Bureau - ASCO; AstraZeneca/MedImmune; MSD Oncology; Nucleix; Roche
Travel, Accommodations, Expenses - European Association of Urology